Cannabinoid receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Cannabinoid Receptors [26]) are activated by endogenous ligands that include N-arachidonoylethanolamine (anandamide), N-homo-γ-linolenoylethanolamine, N-docosatetra-7,10,13,16-enoylethanolamine and 2-arachidonoylglycerol. Potency determinations of endogenous agonists at these receptors are complicated by the possibility of differential susceptibility of endogenous ligands to enzymatic conversion [1].

There are currently three licenced cannabinoid medicines each of which contains a compound that can activate CB₁ and CB₂ receptors [25]. Two of these medicines were developed to suppress nausea and vomiting produced by chemotherapy. These are nabilone (Cesamet®), a synthetic CB₁/CB₂ receptor agonist, and synthetic Δ⁹-tetrahydrocannabinol (Marinol®; dronabinol), which can also be used as an appetite stimulant. The third medicine, Sativex®, contains mainly Δ⁹-tetrahydrocannabinol and cannabidiol, both extracted from cannabis, and is used to treat multiple sclerosis and cancer pain.

Both CB₁ and CB₂ receptors may be labelled with [³H]CP55940 (0.5 nM; [38]) and [³H]WIN55212-2 (2–2.4 nM; [40-41]). Anandamide is also an agonist at vanilloid receptors (TRPV1) and PPARs [23,45]. There is evidence for an allosteric site on the CB₁ receptor [29]. All of the compounds listed as antagonists behave as inverse agonists in some bioassay systems [26]. For some cannabinoid receptor ligands, additional pharmacological targets that include GPR55 and GPR119 have been identified [26]. Moreover, GPR18, GPR55 and GPR119, although showing little structural similarity to CB₁ and CB₂ receptors, respond to endogenous agents that are structurally similar to the endogenous cannabinoid ligands [26].

* Key recommended reading is highlighted with an asterisk

Alexander SP, Kendall DA. (2007) The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol, 152 (5): 602-23. [PMID:17876303]

Bosier B, Muccioli GG, Hermans E, Lambert DM. (2010) Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities. Biochem Pharmacol, 80 (1): 1-12. [PMID:20206137]

Bradshaw HB, Lee SH, McHugh D. (2009) Orphan endogenous lipids and orphan GPCRs: a good match. Prostaglandins Other Lipid Mediat, 89 (3-4): 131-4. [PMID:19379823]

Centonze D, Finazzi-Agrò A, Bernardi G, Maccarrone M. (2007) The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci, 28 (4): 180-7. [PMID:17350694]

Di Marzo V, Bisogno T, De Petrocellis L. (2007) Endocannabinoids and related compounds: walking back and forth between plant natural products and animal physiology. Chem Biol, 14 (7): 741-56. [PMID:17656311]

Di Marzo V, Petrocellis LD. (2006) Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med, 57: 553-74. [PMID:16409166]

Di Marzo V, Petrosino S. (2007) Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol, 18 (2): 129-40. [PMID:17353660]

Fernández-Ruiz J, Romero J, Velasco G, Tolón RM, Ramos JA, Guzmán M. (2007) Cannabinoid CB2 receptor: a new target for controlling neural cell survival?. Trends Pharmacol Sci, 28 (1): 39-45. [PMID:17141334]

Godlewski G, Offertáler L, Wagner JA, Kunos G. (2009) Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins Other Lipid Mediat, 89 (3-4): 105-11. [PMID:19615459]

Hansen HS, Diep TA. (2009) N-acylethanolamines, anandamide and food intake. Biochem Pharmacol, 78 (6): 553-60. [PMID:19413995]

* Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR et al.. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev, 54 (2): 161-202. [PMID:12037135]

Howlett AC, Reggio PH, Childers SR, Hampson RE, Ulloa NM, Deutsch DG. (2011) Endocannabinoid tone versus constitutive activity of cannabinoid receptors. Br J Pharmacol, 163 (7): 1329-43. [PMID:21545414]

Izzo AA, Sharkey KA. (2010) Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther, 126 (1): 21-38. [PMID:20117132]

Maccarrone M, Gasperi V, Catani MV, Diep TA, Dainese E, Hansen HS, Avigliano L. (2010) The endocannabinoid system and its relevance for nutrition. Annu Rev Nutr, 30: 423-40. [PMID:20645854]

McPartland JM, Glass M, Pertwee RG. (2007) Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br J Pharmacol, 152 (5): 583-93. [PMID:17641667]

Mechoulam R, Parker LA. (2013) The endocannabinoid system and the brain. Annu Rev Psychol, 64: 21-47. [PMID:22804774]

Miller LK, Devi LA. (2011) The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol Rev, 63 (3): 461-70. [PMID:21752875]

O'Sullivan SE. (2007) Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol, 152 (5): 576-82. [PMID:17704824]

* Pertwee RG. (2010) Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem, 17 (14): 1360-81. [PMID:20166927]

* Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K et al.. (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev, 62 (4): 588-631. [PMID:21079038]

Ross RA. (2011) L-α-lysophosphatidylinositol meets GPR55: a deadly relationship. Trends Pharmacol Sci, 32 (5): 265-9. [PMID:21367464]

Sharir H, Abood ME. (2010) Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther, 126 (3): 301-13. [PMID:20298715]

Ueda N, Tsuboi K, Uyama T. (2010) Enzymological studies on the biosynthesis of N-acylethanolamines. Biochim Biophys Acta, 1801 (12): 1274-85. [PMID:20736084]

1. Alexander SP, Kendall DA. (2007) The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol, 152 (5): 602-23. [PMID:17876303]

2. Bayewitch M, Rhee MH, Avidor-Reiss T, Breuer A, Mechoulam R, Vogel Z. (1996) (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem, 271 (17): 9902-5. [PMID:8626625]

3. Bowles NP, Karatsoreos IN, Li X, Vemuri VK, Wood JA, Li Z, Tamashiro KL, Schwartz GJ, Makriyannis AM, Kunos G et al.. (2015) A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome. Proc Natl Acad Sci USA, 112 (1): 285-90. [PMID:25535367]

4. Breivogel CS, Sim LJ, Childers SR. (1997) Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J Pharmacol Exp Ther, 282 (3): 1632-42. [PMID:9316881]

5. Di Marzo V, Bisogno T, De Petrocellis L, Brandi I, Jefferson RG, Winckler RL, Davis JB, Dasse O, Mahadevan A, Razdan RK, Martin BR. (2001) Highly selective CB₁ cannabinoid receptor ligands and novel CB₁/VR1 vanilloid receptor "hybrid" ligands. Biochem Biophys Res Commun, 281: 444-451. [PMID:11181068]

6. Felder CC, Joyce KE, Briley EM, Glass M, Mackie KP, Fahey KJ, Cullinan GJ, Hunden DC, Johnson DW, Chaney MO et al.. (1998) LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther, 284 (1): 291-7. [PMID:9435190]

7. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL, Mitchell RL. (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol, 48 (3): 443-50. [PMID:7565624]

8. Gado F, Di Cesare Mannelli L, Lucarini E, Bertini S, Cappelli E, Digiacomo M, Stevenson LA, Macchia M, Tuccinardi T, Ghelardini C et al.. (2019) Identification of the First Synthetic Allosteric Modulator of the CB₂ Receptors and Evidence of Its Efficacy for Neuropathic Pain Relief. J Med Chem, 62 (1): 276-287. [PMID:29990428]

9. Gareau Y, Dufresne C, Gallant M, Rochette C, Sawyer N, Slipetz DM, Tremblay N, Weech PK, Metters KM, Labelle M. (1996) Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors. Bioorg Med Chem Lett, 6: 189-194.

10. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, Pertwee RG, Ross RA, Mechoulam R, Fride E. (1999) HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA, 96 (25): 14228-33. [PMID:10588688]

11. Hillard CJ, Manna S, Greenberg MJ, DiCamelli R, Ross RA, Stevenson LA, Murphy V, Pertwee RG, Campbell WB. (1999) Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther, 289 (3): 1427-33. [PMID:10336536]

12. Hirst RA, Almond SL, Lambert DG. (1996) Characterisation of the rat cerebella CB1 receptor using SR141716A, a central cannabinoid receptor antagonist. Neurosci Lett, 220 (2): 101-4. [PMID:8981483]

13. Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL, Martin BR. (1999) 3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem, 7 (12): 2905-14. [PMID:10658595]

14. Ignatowska-Jankowska BM, Baillie GL, Kinsey S, Crowe M, Ghosh S, Owens RA, Damaj IM, Poklis J, Wiley JL, Zanda M et al.. (2015) A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects. Neuropsychopharmacology, 40 (13): 2948-59. [PMID:26052038]

15. Jung M, Calassi R, Rinaldi Carmona M, Chardenot P, Le Fur G, Soubrie P, Oury-Donat F. (1997) Characterization of CB₁ receptors on rat neuronal cell cultures: binding and functional studies using the selective receptor antagonist SR 141716A. J Neurochem, 68: 402-409. [PMID:8978752]

16. Khanolkar AD, Abadji V, Lin S, Hill WA, Taha G, Abouzid K, Meng Z, Fan P, Makriyannis A. (1996) Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J Med Chem, 39 (22): 4515-9. [PMID:8893848]

17. Kulkarni PM, Kulkarni AR, Korde A, Tichkule RB, Laprairie RB, Denovan-Wright EM, Zhou H, Janero DR, Zvonok N, Makriyannis A et al.. (2016) Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s). J Med Chem, 59 (1): 44-60. [PMID:26529344]

18. Lan R, Gatley J, Lu Q, Fan P, Fernando SR, Volkow ND, Pertwee R, Makriyannis A. (1999) Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand. AAPS PharmSci, 1 (2): E4. [PMID:11741201]

19. Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D, Pertwee R, Makriyannis A. (1999) Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem, 42 (4): 769-76. [PMID:10052983]

20. Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol, 172 (20): 4790-805. [PMID:26218440]

21. Laprairie RB, Kulkarni PM, Deschamps JR, Kelly MEM, Janero DR, Cascio MG, Stevenson LA, Pertwee RG, Kenakin TP, Denovan-Wright EM et al.. (2017) Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor. ACS Chem Neurosci, 8 (6): 1188-1203. [PMID:28103441]

22. Marini P, Cascio MG, King A, Pertwee RG, Ross RA. (2013) Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors. Br J Pharmacol, 169 (4): 887-99. [PMID:23711022]

23. O'Sullivan SE. (2007) Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol, 152 (5): 576-82. [PMID:17704824]

24. Pertwee RG. (2000) Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opin Investig Drugs, 9 (7): 1553-71. [PMID:11060760]

25. Pertwee RG. (2012) Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond, B, Biol Sci, 367 (1607): 3353-63. [PMID:23108552]

26. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K et al.. (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev, 62 (4): 588-631. [PMID:21079038]

27. Petitet F, Marin L, Doble A. (1996) Biochemical and pharmacological characterization of cannabinoid binding sites using [³H]SR141716A. Neuroreport, 7: 789-792. [PMID:8733746]

28. Petrucci V, Chicca A, Glasmacher S, Paloczi J, Cao Z, Pacher P, Gertsch J. (2017) Pepcan-12 (RVD-hemopressin) is a CB2 receptor positive allosteric modulator constitutively secreted by adrenals and in liver upon tissue damage. Sci Rep, 7 (1): 9560. [PMID:28842619]

29. Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R, McLean A, McIntosh L, Goodwin G, Walker G et al.. (2005) Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol, 68 (5): 1484-95. [PMID:16113085]

30. Rhee MH, Vogel Z, Barg J, Bayewitch M, Levy R, Hanus L, Breuer A, Mechoulam R. (1997) Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem, 40 (20): 3228-33. [PMID:9379442]

31. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D et al.. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett, 350 (2-3): 240-4. [PMID:8070571]

32. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B et al.. (1998) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther, 284 (2): 644-50. [PMID:9454810]

33. Rinaldi-Carmona M, Pialot F, Congy C, Redon E, Barth F, Bachy A, Breliere JC, Soubrie P, Le Fur G. (1996) Characterization and distribution of binding sites for [³H]-SR 141716A, a selective brain (CB₁) cannabinoid receptor antagonist, in rodent brain. Life Sci, 58: 1239-1247. [PMID:8614277]

34. Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, Pertwee RG. (1999) Agonist-inverse agonist characterization at CB₁ and CB₂ cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol, 126: 665-672. [PMID:10188977]

35. Ruiu S, Pinna GA, Marchese G, Mussinu JM, Saba P, Tambaro S, Casti P, Vargiu R, Pani L. (2003) Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor. J Pharmacol Exp Ther, 306 (1): 363-70. [PMID:12663689]

36. Shire D, Calandra B, Rinaldi-Carmona M, Oustric D, Pessègue B, Bonnin-Cabanne O, Le Fur G, Caput D, Ferrara P. (1996) Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim Biophys Acta, 1307 (2): 132-6. [PMID:8679694]

37. Shire D, Carillon C, Kaghad M, Calandra B, Rinaldi-Carmona M, Le Fur G, Caput D, Ferrara P. (1995) An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem, 270 (8): 3726-31. [PMID:7876112]

38. Showalter VM, Compton DR, Martin BR, Abood ME. (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther, 278 (3): 989-99. [PMID:8819477]

39. Sim LJ, Hampson RE, Deadwyler SA, Childers SR. (1996) Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain. J Neurosci, 16 (24): 8057-66. [PMID:8987831]

40. Slipetz DM, O'Neill GP, Favreau L, Dufresne C, Gallant M, Gareau Y, Guay D, Labelle M, Metters KM. (1995) Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol Pharmacol, 48 (2): 352-61. [PMID:7651369]

41. Song ZH, Bonner TI. (1996) A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol Pharmacol, 49 (5): 891-6. [PMID:8622639]

42. Tam J, Cinar R, Liu J, Godlewski G, Wesley D, Jourdan T, Szanda G, Mukhopadhyay B, Chedester L, Liow JS et al.. (2012) Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab, 16 (2): 167-79. [PMID:22841573]

43. Thomas BF, Gilliam AF, Burch DF, Roche MJ, Seltzman HH. (1998) Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther, 285 (1): 285-92. [PMID:9536023]

44. Yao BB, Mukherjee S, Fan Y, Garrison TR, Daza AV, Grayson GK, Hooker BA, Dart MJ, Sullivan JP, Meyer MD. (2006) In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor?. Br J Pharmacol, 149 (2): 145-54. [PMID:16894349]

45. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sørgård M, Di Marzo V, Julius D, Högestätt ED. (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature, 400 (6743): 452-7. [PMID:10440374]

Subcommittee members: Roger G. Pertwee (Chairperson) School of Medical Sciences Institute of Medical Sciences University of Aberdeen Foresterhill Aberdeen AB25 2ZD UK Allyn C. Howlett (Past chairperson) Neuroscience of Drug Abuse Research Program Julius L. Chambers Biomedical/Biotechnology Research Institute North Carolina Central University 700 George Street Durham NC 27707 USA Mary Abood California Pacific Med Ctr San Francisco CA 94115 USA Stephen P.H. Alexander Associate Professor in Molecular Pharmacology Life Sciences E Floor University of Nottingham Medical School Nottingham NG7 2UH UK Heather Bradshaw Psychological and Brain Sciences Indiana University 1101 East 10th Street Bloomington, IN 47405 USA Guy Cabral Microbiology and Immunology Department Medical College of Virginia Room 6040 1101 E. Marshall Street Richmond VA 23219 USA Vincenzo Di Marzo Via Campi Flegrei 34, Fabbr. 70 Pozzuoli Napoli 80078 Italy Maurice R. Elphick Queen Mary University London London E1 4NS UK Peter Greasley Department of Molecular Pharmacology AstraZeneca R&D Mölndal S-431 83 Mölndal Sweden George Kunos Lab. Physiol. Studies NIAAA NIH Bethesda MD 20892 USA Ken Mackie Dept. Anesthesiology University of Washington Seattle WA 98195 USA Raphael Mechoulam Department of Natural Products Faculty of Medicine of Hebrew University Jerusalem 91120 Israel

Other contributors: Francis Barth Sanofi Synthelabo Recherche Montpellier 34184 France Tom I. Bonner (Past Core Member) Special Volunteer Office of Science Director NIMH Bethesda MD USA Pierre Casellas Sanofi Recherche Centre de Montpellier 371 rue du Professeur Joseph-Blayac Montpellier 34184 France Ben F. Cravatt Skaggs Institute for Chemical Biology Scripps Research Institute La Jolla CA 92037 USA William A. Devane Department of Pharmacology and Toxicology Medical College of Virginia Box 613 MCV Station Richmond VA 23298-0613 USA Christian C. Felder Lilly Research Laboratories Lilly Corporate Center Drop 0510 Indianapolis IN 46285 USA Miles Herkenham Section of Functional Neuroanatomy National Institute of Mental Health Building 36 Room 2D15 36 Convent Drive Bethesda MD 20892-4070 USA Ruth A. Ross University of Toronto Department of Pharmacology & Toxicology Medical Sciences Building, Room 4207 1 King's College Circle Toronto, Ontario M5S 1A8 Canada